{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:19:47Z","timestamp":1787019587367,"version":"build-2736575974"},"reference-count":35,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Although TP53 is commonly mutated in transformed follicular lymphoma, mutations are reported in &amp;lt;5% of pretreatment follicular lymphoma (FL) specimens. We assayed archival follicular B-cell non-Hodgkin lymphoma specimens from a completed clinical trial, Southwest Oncology Group S0016, a phase 3 randomized intergroup trial of CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone) chemotherapy plus R-CHOP (rituximab-CHOP) compared with CHOP chemotherapy plus 131-iodine tositumomab (radioimmunotherapy [RIT]-CHOP). Subclonal TP53 mutations (median allele frequency 0.02) were found in 25% of diagnostic FL specimens and in 27% of a separate validation cohort. In the R-CHOP arm, pathogenic TP53 mutations were not associated with progression-free survival (PFS) (10-year PFS 43% vs 44%). In contrast, among patients with no detectable pathogenic TP53 mutation, RIT-CHOP was associated with a longer PFS than with R-CHOP (10-year PFS 67% vs 44%; hazard ratio\u00a0= 0.49; P\u00a0= .008). No relationship was\u00a0detected between PFS and the extent of activation-induced cytidine deaminase (AICDA)\u2013mediated heterogeneity. In summary, subclonal TP53 mutations are common in FL and are a distinct phenomenon from AICDA-mediated genetic heterogeneity. The absence of a detectable subclonal mutation in TP53 defined a population that particularly benefited from RIT.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022009467","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T13:14:15Z","timestamp":1687958055000},"page":"5082-5090","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5584-584X","authenticated-orcid":false,"given":"W. Richard","family":"Burack","sequence":"first","affiliation":[{"name":"1Department of Pathology, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Li","sequence":"additional","affiliation":[{"name":"2Clinical Research Division, Fred Hutchison Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9878-1745","authenticated-orcid":false,"given":"Diana","family":"Adlowitz","sequence":"additional","affiliation":[{"name":"1Department of Pathology, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice M.","family":"Spence","sequence":"additional","affiliation":[{"name":"1Department of Pathology, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Rimsza","sequence":"additional","affiliation":[{"name":"3Department of Laboratory Medicine and Pathology, Mayo Clinic in Arizona, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-6562","authenticated-orcid":false,"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[{"name":"2Clinical Research Division, Fred Hutchison Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Spier","sequence":"additional","affiliation":[{"name":"4Department of Pathology, The University of Arizona, Tuscon, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Kaminski","sequence":"additional","affiliation":[{"name":"5Department of Internal Medicine, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[{"name":"6Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Leblanc","sequence":"additional","affiliation":[{"name":"2Clinical Research Division, Fred Hutchison Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9893-4949","authenticated-orcid":false,"given":"Sonali M.","family":"Smith","sequence":"additional","affiliation":[{"name":"7Department of Medicine, University of Chicago School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[{"name":"8Department of Medicine, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,8,28]]},"reference":[{"issue":"1","key":"2023091115441062400_bib1","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/imr.12745","article-title":"Molecular pathogenesis of germinal center-derived B cell lymphomas","volume":"288","author":"Pasqualucci","year":"2019","journal-title":"Immunol Rev"},{"issue":"1","key":"2023091115441062400_bib2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/ng.2007.35","article-title":"AID is required for germinal center-derived lymphomagenesis","volume":"40","author":"Pasqualucci","year":"2008","journal-title":"Nat Genet"},{"issue":"1","key":"2023091115441062400_bib3","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","article-title":"Genetics of follicular lymphoma transformation","volume":"6","author":"Pasqualucci","year":"2014","journal-title":"Cell Rep"},{"issue":"1","key":"2023091115441062400_bib4","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2014-04-516815","article-title":"Transformed follicular non-Hodgkin lymphoma","volume":"125","author":"Casulo","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2023091115441062400_bib5","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1182\/blood-2014-04-571786","article-title":"BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma","volume":"125","author":"Correia","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2023091115441062400_bib6","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.leukres.2007.11.028","article-title":"Quantifying the role of aberrant somatic hypermutation in transformation of follicular lymphoma","volume":"32","author":"Halldorsdottir","year":"2008","journal-title":"Leuk Res"},{"issue":"7381","key":"2023091115441062400_bib7","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nature10762","article-title":"Clonal evolution in cancer","volume":"481","author":"Greaves","year":"2012","journal-title":"Nature"},{"issue":"6","key":"2023091115441062400_bib8","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/ajh.24701","article-title":"BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab","volume":"92","author":"Huet","year":"2017","journal-title":"Am J Hematol"},{"issue":"4","key":"2023091115441062400_bib9","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1365-2559.2009.03241.x","article-title":"The expression of activation induced cytidine deaminase in follicular lymphoma is independent of prognosis and stage","volume":"54","author":"Willenbrock","year":"2009","journal-title":"Histopathology"},{"issue":"12","key":"2023091115441062400_bib10","doi-asserted-by":"crossref","first-page":"e1002197","DOI":"10.1371\/journal.pmed.1002197","article-title":"Histological transformation and progression in follicular lymphoma: a clonal evolution study","volume":"13","author":"Kridel","year":"2016","journal-title":"PLoS Med"},{"issue":"5","key":"2023091115441062400_bib11","doi-asserted-by":"crossref","first-page":"8765","DOI":"10.18632\/oncotarget.14448","article-title":"The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma","volume":"8","author":"Sarkozy","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"2023091115441062400_bib12","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/sj.leu.2403488","article-title":"AID is expressed in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas and is not correlated with intraclonal heterogeneity","volume":"18","author":"Lossos","year":"2004","journal-title":"Leukemia"},{"issue":"1","key":"2023091115441062400_bib13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/10428194.2015.1037758","article-title":"Isotype-switched follicular lymphoma displays dissociation between activation-induced cytidine deaminase expression and somatic hypermutation","volume":"57","author":"Scherer","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2023091115441062400_bib14","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1182\/blood-2008-05-154013","article-title":"The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival","volume":"112","author":"O'Shea","year":"2008","journal-title":"Blood"},{"issue":"14","key":"2023091115441062400_bib15","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1182\/blood-2013-11-539726","article-title":"Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia","volume":"123","author":"Rossi","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2023091115441062400_bib16","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.2012.42.4101","article-title":"Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016","volume":"31","author":"Press","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2023091115441062400_bib17","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2017.74.5083","article-title":"Continued excellent outcomes in previously untreated patients with follicular lymphoma after treatment with CHOP plus rituximab or CHOP plus (131)I-tositumomab: long-term follow-up of phase III randomized study SWOG-S0016","volume":"36","author":"Shadman","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2023091115441062400_bib18","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.4049\/jimmunol.1401699","article-title":"Intraclonal diversity in follicular lymphoma analyzed by quantitative ultradeep sequencing of noncoding regions","volume":"193","author":"Spence","year":"2014","journal-title":"J\u00a0Immunol"},{"key":"2023091115441062400_bib19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.anndiagpath.2019.05.004","article-title":"TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant","volume":"41","author":"Sakhdari","year":"2019","journal-title":"Ann Diagn Pathol"},{"issue":"23","key":"2023091115441062400_bib20","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study","volume":"33","author":"Casulo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2023091115441062400_bib21","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","article-title":"Evolution and impact of subclonal mutations in chronic lymphocytic leukemia","volume":"152","author":"Landau","year":"2013","journal-title":"Cell"},{"issue":"9","key":"2023091115441062400_bib22","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"2023091115441062400_bib23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0092-8674(95)90412-3","article-title":"Tumor suppressor p53 is a direct transcriptional activator of the human bax gene","volume":"80","author":"Miyashita","year":"1995","journal-title":"Cell"},{"issue":"6423","key":"2023091115441062400_bib24","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/362847a0","article-title":"p53 is required for radiation-induced apoptosis in mouse thymocytes","volume":"362","author":"Lowe","year":"1993","journal-title":"Nature"},{"issue":"4","key":"2023091115441062400_bib25","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood-2007-01-067579","article-title":"In\u00a0vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma","volume":"110","author":"Knoops","year":"2007","journal-title":"Blood"},{"issue":"6","key":"2023091115441062400_bib26","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1182\/blood.V99.6.2192","article-title":"Tumor cell dissemination in follicular lymphoma","volume":"99","author":"Oeschger","year":"2002","journal-title":"Blood"},{"issue":"2","key":"2023091115441062400_bib27","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat Genet"},{"issue":"1","key":"2023091115441062400_bib28","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nm.3984","article-title":"Pan-cancer analysis of the extent and consequences of intratumor heterogeneity","volume":"22","author":"Andor","year":"2016","journal-title":"Nat Med"},{"issue":"6","key":"2023091115441062400_bib29","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.cell.2019.02.012","article-title":"Characterizing mutational signatures in human cancer cell lines reveals episodic APOBEC mutagenesis","volume":"176","author":"Petljak","year":"2019","journal-title":"Cell"},{"issue":"12","key":"2023091115441062400_bib30","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1172\/JCI72415","article-title":"Germinal center reentries of BCL2-overexpressing B cells drive follicular lymphoma progression","volume":"124","author":"Sungalee","year":"2014","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"2023091115441062400_bib31","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41467-017-02595-w","article-title":"AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis","volume":"9","author":"Teater","year":"2018","journal-title":"Nat Commun"},{"issue":"9","key":"2023091115441062400_bib32","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/ng.2702","article-title":"An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers","volume":"45","author":"Roberts","year":"2013","journal-title":"Nat Genet"},{"issue":"7","key":"2023091115441062400_bib33","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1158\/2159-8290.CD-15-0344","article-title":"APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity","volume":"5","author":"Swanton","year":"2015","journal-title":"Cancer Discov"},{"issue":"12","key":"2023091115441062400_bib34","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2004-12-4690","article-title":"Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab","volume":"105","author":"Bennett","year":"2005","journal-title":"Blood"},{"issue":"1","key":"2023091115441062400_bib35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1182\/blood-2018-07-865428","article-title":"Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016","volume":"133","author":"Qu","year":"2019","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/17\/5082\/2077042\/blooda_adv-2022-009467-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/17\/5082\/2077042\/blooda_adv-2022-009467-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T11:44:45Z","timestamp":1694432685000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/17\/5082\/496557\/Subclonal-TP53-mutations-are-frequent-and-predict"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,28]]},"references-count":35,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023,9,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022009467","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,28]]}}}